Market Overview - Wall Street experienced a significant rebound after a volatile week, driven by dovish comments from Federal Reserve officials suggesting potential rate cuts next month [1][2] - The probability of a December rate cut surged to approximately 70%, up from 25% the previous day, indicating a rapid shift in market expectations [3] Sector Performance - Interest-sensitive stocks rallied strongly, with the small-cap Russell 2000 rising by 2.8%, marking its best single-day gain since late August [3] - All 11 S&P 500 sectors saw gains, particularly basic materials and consumer discretionary, both increasing by 2.6% [3] Homebuilders - Homebuilder stocks, tracked by the State Street SPDR S&P Homebuilder ETF (NYSE:XHB), surged by 5.3%, the best performance since April 9, with D.R. Horton Inc. (NYSE:DHI) climbing over 7% [4] Treasury Yields - Following the dovish shift, Treasury yields fell, with the 10-year note dropping to 4.05%, the lowest level since late October [4] AI Sector - Despite the overall positive market tone, investors continued to sell off AI stocks with high valuations, with Oracle Corp. (NYSE:ORCL) declining by 5% on Friday, extending its weekly loss to 10% [5] Commodities - Oil prices decreased by 2% after Ukrainian President Volodymyr Zelenskiy expressed openness to peace talks, raising concerns about oversupply [6] Cryptocurrency - The cryptocurrency market remained under pressure, with Bitcoin (CRYPTO: BTC) falling to an intraday low of $80,000 before recovering to $85,000, down 1.7% for the day [7] Major Indices Performance - Major U.S. indices showed positive performance, with the Russell 2000 up 2.7%, Dow Jones up 1.5%, S&P 500 up 1.2%, and Nasdaq 100 up 1.0% [8] Top Gainers and Laggards - Top gainers in the Russell 1000 included WillScot Mobile Mini Holdings Corp. (NASDAQ:WSC) up 11.89% and CAVA Group Inc. (NYSE:CAVA) up 10.57% [9] - Top laggards included Elastic N.V. (NYSE:ESTC) down 12.83% and Veeva Systems Inc. (NYSE:VEEV) down 10.55% [10]

Economic Indicators - The University of Michigan's US Nov 1-year inflation expectations were revised lower to 4.5% from 4.7% and the Nov 5-10 year inflation expectations were revised lower to 3.4% from 3.6% [2] - The US Nov consumer sentiment index was revised upward by +0.7 to 51.0, stronger than expectations of 50.6 [2] - The US Nov S&P manufacturing PMI fell -0.6 to 51.9, close to expectations of 52.0 [2] Stock Market Performance - US stock indexes were mixed early but extended gains in the afternoon, with the S&P 500 Index up by +1.38%, the Dow Jones up by +1.52%, and the Nasdaq 100 up by +1.14% [5] - Stock indexes initially moved higher due to comments from New York Fed President John Williams, which increased the chance of a Fed rate cut at the next FOMC meeting to 70% from 35% [3][7] Corporate Earnings - Q3 corporate earnings season is concluding, with 82% of reporting S&P 500 companies exceeding forecasts, leading to a +14.6% increase in earnings, more than doubling expectations of +7.2% y/y [8] - Home builders and building suppliers saw gains as the 10-year T-note yield fell to a 3-week low, with companies like DR Horton up more than +5% [14] Cryptocurrency Market - The price of Bitcoin fell by more than -2% to a 7.25-month low, continuing a sharp 6-week downtrend with prices down more than 35% from a record high last month [6] - Cryptocurrency-exposed stocks faced pressure, with notable declines in companies like Strategy down more than -6% and Galaxy Digital Holdings down more than -5% [16] International Markets - Overseas stock markets were lower, with the Euro Stoxx 50 down -0.95%, China's Shanghai Composite down -2.45%, and Japan's Nikkei Stock 225 down -2.40% [9][12]

Market Overview - U.S. stock futures showed volatility with mixed performance after a significant sell-off on Thursday, with the S&P 500 index dropping below key support levels [1][2] - The S&P 500 index fell below its 50-day moving average for the first time in months, indicating potential bearish sentiment [1] Economic Indicators - September's job report revealed non-farm payrolls increased by 119,000, significantly exceeding the forecast of 50,000, which dampened expectations for interest rate cuts [2] - The 10-year Treasury bond yield was at 4.08%, while the two-year bond yield stood at 3.53%, reflecting market sentiment on interest rates [2] Futures Performance - Dow Jones futures increased by 0.28%, while S&P 500 and Nasdaq 100 futures decreased by 0.14% and 0.47%, respectively [3] - The SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ Trust ETF (QQQ) both experienced declines in premarket trading, with SPY down 0.35% and QQQ down 0.77% [3] Company Highlights - New Fortress Energy Inc. surged by 19.86% due to successful debt restructuring efforts [5] - Gap Inc. advanced by 3.86% after reporting strong third-quarter results and raising its FY25 sales guidance [5] - Veeva Systems Inc. saw a decline of 6.69% despite positive third-quarter results and raised fiscal year estimates [4][5] - Elastic NV dropped by 12.21% despite a solid earnings beat and strong guidance for the current quarter [5] - Intuit Inc. rose by 3.23% after reporting better-than-expected first-quarter results, although it expects second-quarter adjusted earnings to be below estimates [14] Analyst Insights - Scott Wren from Wells Fargo Investment Institute maintains a bullish outlook for the equity market through 2026, forecasting an accelerating economy driven by deregulation and expected Federal Reserve rate cuts [10][11] - Wren suggests reallocating investments from fully valued technology sectors into Financials and Industrials, which are expected to benefit from AI infrastructure growth [12]

Market Overview - U.S. stock futures showed volatility with mixed performance after a significant sell-off on Thursday, with the S&P 500 index dropping below the support line of 6,550 and its 50-day moving average for the first time in months [1][2] - The September job report revealed non-farm payrolls increased by 119,000, exceeding economists' expectations of 50,000, impacting market expectations for interest rate cuts [2] Futures Performance - Dow Jones futures increased by 0.28%, while S&P 500 and Nasdaq 100 futures decreased by 0.14% and 0.47%, respectively [3] - The SPDR S&P 500 ETF Trust (SPY) fell by 0.35% to $650.25, and the Invesco QQQ Trust ETF (QQQ) declined by 0.77% to $581.15 in premarket trading [3] Stocks in Focus - New Fortress Energy Inc. surged by 19.86% due to debt restructuring efforts, while Gap Inc. rose by 3.86% after positive third-quarter results and an increase in FY25 sales guidance [4][5] - Veeva Systems Inc. dropped by 6.69% despite strong quarterly results and raised fiscal year estimates, while Elastic NV fell by 12.21% despite a solid earnings beat and strong guidance [4][5] Analyst Insights - Scott Wren from Wells Fargo Investment Institute maintains a bullish outlook for the equity market through 2026, forecasting an accelerating economy driven by deregulation and expected Federal Reserve rate cuts [10][11] - Wren advises reallocating investments from fully valued technology sectors into Financials and Industrials, which are expected to benefit from AI infrastructure growth [12] Upcoming Economic Data - Investors are anticipating key economic data releases, including November's S&P flash U.S. services and manufacturing PMI and final consumer sentiment data [15]

Group 1: Earnings Reports and Expectations - BJ's Wholesale Club Holdings Inc. is expected to report quarterly earnings of $1.09 per share on revenue of $5.35 billion [2] - Veeva Systems Inc. posted strong third-quarter results and raised its fiscal year earnings and revenue estimates above analyst expectations [2] - IES Holdings Inc. is anticipated to report quarterly earnings of $3.11 per share on revenue of $843 million [2] - Intuit Inc. reported better-than-expected first-quarter results and expects second-quarter revenue growth of approximately 14% to 15% [2] - Gap Inc. reported third-quarter earnings of 62 cents per share, exceeding the analyst estimate of 59 cents, with quarterly revenue of $3.94 billion [2] Group 2: Stock Performance - BJ's Wholesale shares fell 0.6% to $90.06 in after-hours trading [2] - Veeva shares dipped 6.7% to $252.40 in after-hours trading [2] - IES shares fell 0.3% to $357.00 in after-hours trading [2] - Intuit shares gained 3.2% to $658.00 in after-hours trading [2] - Gap shares gained 5.5% to $24.32 in after-hours trading [2]

Core Insights - Veeva Systems Inc. is recognized as a leading digital health stock, particularly in the life sciences sector [1] - The company announced that its Veeva Basics solution has been adopted by over 100 biotech firms, indicating strong market demand and scalability [2][5] - New capabilities include LIMS Basics for laboratory oversight and PromoMats Basics for content lifecycle management, enhancing operational efficiency for users [3][4] Company Overview - Veeva Systems Inc. operates as a cloud-software company focused on providing solutions for life sciences organizations, including clinical, regulatory, quality, and commercial platforms [6] - The Veeva Basics solution is built on the Vault Platform, allowing biotech firms to implement best practices quickly and transition smoothly to a full Vault solution [2][4] Market Position - The adoption of Veeva Basics by over 100 firms highlights Veeva's strategic growth within the emerging biotech segment, where regulatory compliance and cost efficiency are critical [5] - Testimonials from early adopters emphasize the benefits of pre-configured templates and rapid implementation, showcasing Veeva's value proposition in the market [4]

Financial Performance - Biotricity Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.07 per share a year ago, representing an earnings surprise of +62.50% [1] - The company posted revenues of $3.89 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.36%, but showing an increase from $3.27 million in the same quarter last year [2] Stock Performance - Biotricity shares have increased approximately 82.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.6% [3] - The current Zacks Rank for Biotricity is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $4.1 million, and for the current fiscal year, it is -$0.32 on revenues of $15.8 million [7] - The estimate revisions trend for Biotricity was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - Biotricity operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - DarioHealth Corp. reported a quarterly loss of $1.85 per share, which was better than the Zacks Consensus Estimate of a loss of $2.63, representing an earnings surprise of +29.66% [1] - The company posted revenues of $5.01 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 12.47%, and down from $7.42 million a year ago [2] - DarioHealth shares have declined approximately 25.3% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.54 on revenues of $6.41 million, and for the current fiscal year, it is -$9.83 on revenues of $24.25 million [7] - The estimate revisions trend for DarioHealth was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which DarioHealth belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Medtronic (MDT) is scheduled to announce its second-quarter fiscal 2026 results on November 18, with expectations of strong performance based on previous earnings surprises [1][2] Group 1: Financial Performance Estimates - The Zacks Consensus Estimate for Medtronic's revenues in the fiscal second quarter is $8.86 billion, indicating a 5.4% year-over-year increase [2] - The consensus estimate for EPS is projected to rise 4% to $1.31, with earnings estimates remaining unchanged over the past 60 days [2] Group 2: Segment Performance Cardiovascular - The Cardiovascular segment is expected to show strong momentum, with revenues projected to increase by 8.4% year over year, driven by the uptake of PulseSelect and Affera Sphere-9 systems [3][5] - The Evolut FX+ TAVR device is likely to gain traction in various markets, including Japan, benefiting from a competitor's exit [4] Neuroscience - Neuroscience revenues are anticipated to grow by 1.5% year over year, supported by strong sales in Cranial & Spinal Technologies and the adoption of AiBLE spine technology [6][8] - Neuromodulation performance is expected to benefit from U.S. growth in Pain Stim and the approval of the Altaviva device for treating urge urinary incontinence [7] Medical Surgical - Medtronic's Medical Surgical segment is projected to see a 5.4% year-over-year revenue increase, driven by demand for LigaSure technology and growth in the Advanced Energy product line [10][11] Diabetes - The Diabetes unit is expected to experience a 9.2% year-over-year revenue growth, fueled by the MiniMed 780G and Simplera Sync sensors [9][14] - Key FDA approvals during the quarter, including the SmartGuard algorithm and MiniMed 780G for type 2 diabetes, are likely to contribute to revenue growth [13][14] Group 3: Earnings Expectations - Medtronic currently holds a Zacks Rank of 3 (Hold) with an Earnings ESP of 0.00%, indicating a neutral outlook for beating estimates [15]

Core Insights - The healthcare sector's decline presents stock-picking opportunities, but an overall rebound is unlikely [1] - Year-to-date, the healthcare sector (XLV) has underperformed the S&P 500 by 8 percentage points and is on track to underperform for the third consecutive year [1] - Despite low valuations indicating potential upside, robust economic growth, the AI boom, and policy uncertainties may limit overall sector performance [1] - Alpha opportunities are seen as greater than beta returns, with increasing return rate disparities and active M&A activity in the healthcare sector driving stock selection [1] - Goldman Sachs expects M&A activity to continue growing into next year, with nearly half of its M&A concept stock portfolio consisting of healthcare companies [1] Stock Selection - Goldman Sachs has identified specific healthcare stocks from the Russell 1000 index that have recently seen upward revisions in 2026 EPS forecasts and are currently valued below historical levels [2] - Selected stocks include: Jazz Pharmaceuticals (JAZZ.US), Insulet (PODD.US), Sotera Health (SHC.US), Incyte (INCY.US), Regeneron Pharmaceuticals (REGN.US), Biomarin Pharmaceutical (BMRN.US), Universal Health Services (UHS.US), Doximity (DOCS.US), Endocrine Biosciences (NBIX.US), Vertex Pharmaceuticals (VRTX.US), Illumina (ILMN.US), West Pharmaceutical Services (WST.US), DaVita (DVA.US), Edwards Lifesciences (EW.US), Eli Lilly (LLY.US), Zimmer Biomet Holdings (ZBH.US), Penumbra (PEN.US), Nevro (NVST.US), Medtronic (MDT.US), Veeva Systems (VEEV.US), Masimo (MASI.US), Pfizer (PFE.US), Thermo Fisher Scientific (TMO.US), ResMed (RMD.US), Bio-Rad Laboratories (BIO.US), Certara (CERT.US), Align Technology (ALGN.US), Charles River Laboratories International (CRL.US), and Hologic (HOLX.US) [2]